Stock Market Reviews

DRTS (Alpha Tau Medical Ltd.) News

Get the latest news, insights, and market updates on DRTS (Alpha Tau Medical Ltd.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• HekaBio and Alpha Tau Medical Obtain Approval in Japan for Solid Tumor Treatment Alpha DaRT
  TOKYO, February 25, 2026--Japan approves Alpha DaRT for head & neck cancer, becoming the first market outside Israel.
  Feb 25, 2026 - $DRTS
• Alpha Tau price target raised to $12 from $9 at H.C. Wainwright
  H.C. Wainwright analyst Yi Chen raised the firm’s price target on Alpha Tau (DRTS) to $12 from $9 and keeps a Buy rating on the shares after Japan’s Ministry of Health, Labour and Welfare granted marketing approval for Alpha DaRT for the treatment of unresectable locally advanced or locally recurrent head and neck cancer. The approval in Japan further validates the Alpha DaRT platform and helps de-risk the clinical development in the U.S., the analyst tells investors.Claim 50% Off TipRanks Premi
  Feb 25, 2026 - $DRTS
• Alpha Tau Medical Receives Japanese Marketing Approval for Alpha DaRT® in Unresectable Locally Advanced or Locally Recurrent Head and Neck Cancer
  - Approval establishes first clinical authorization outside Israel and initiates post-market surveillance program - - First-in-kind technology delivers intra-tumoral alpha-emitting radiotherapeutics, reflects strength of clinical data and strong collaboration with Japanese regulators and clinical societies - JERUSALEM, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) (“Alpha Tau”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today ann
  Feb 24, 2026 - $DRTS
• Alpha Tau Issues Letter to Shareholders: Five Concurrent Trials in the U.S. with Multiple Significant Value-Driving Milestones Ahead
  - Expecting very active 2026 from a clinical perspective, including significant patient accrual completions and subsequent data readouts from ReSTART pivotal skin cancer trial as well as trials in cancers of internal organs including the pancreas and brain - - Ramping U.S. manufacturing for commercial readiness - Jerusalem, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT® today
  Jan 29, 2026 - $DRTS
• New Strong Sell Stocks for January 27th
  DRTS, MPC and NRXP have been added to the Zacks Rank #5 (Strong Sell) List on January 27th, 2026.
  Jan 27, 2026 - $DRTS
• DealFlow Discovery Conference Announces Initial Lineup of Presenting Companies Ahead of Next Week's Event
  ATLANTIC CITY, NJ / ACCESS Newswire / January 23, 2026 / DealFlow Events today announced the growing list of companies scheduled to present and participate in one-on-one meetings with investors and analysts at the DealFlow Discovery Conference, taking ...
  Jan 23, 2026 - $DRTS
• New Strong Sell Stocks for January 20th
  DAR, CADL and DRTS have been added to the Zacks Rank #5 (Strong Sell) List on January 20, 2026.
  Jan 20, 2026 - $DRTS
• Peter Melnyk Joins Taiho Oncology as President & Chief Operating Officer
  PRINCETON, N.J., January 20, 2026--Peter Melnyk joins Taiho Oncology as President & Chief Operating Officer.
  Jan 20, 2026 - $DRTS
• Alpha Tau Reports New Positive Results in Two Upcoming Presentations at ASCO GI 2026 Symposium Showcasing Immune-Preservation and High Disease Control in Montreal Pancreatic Cancer Alpha DaRT® Study
  - Final results from first pancreatic cancer study in Montreal demonstrate 81% disease control rate, or 87% excluding the first two patients - - Immune markers demonstrate immune system preservation not typical of conventional radiation therapy treatments, as well as potential anti-inflammatory effect - - Alpha DaRT currently being studied together with first-line chemotherapy in U.S. multi-center pilot trial for newly diagnosed pancreatic cancer - JERUSALEM, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Al
  Jan 6, 2026 - $DRTS
• Alpha Tau Submits First Pre-Market Approval Module to the FDA for Alpha DaRT® for the Treatment of Recurrent Cutaneous Squamous Cell Carcinoma (cSCC)
  - Initial module submission marks an important milestone in the pre-market approval process - - Flexible modular submission framework granted to Alpha Tau by the FDA allows for streamlined review and feedback from the FDA as each module is submitted - - Module submitted in parallel to execution of ReSTART pivotal study (Recurrent SCC Treatment with Alpha DaRT Radiation Therapy), which is expected to complete recruiting patients in Q1 2026 - JERUSALEM, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Alpha Tau
  Jan 5, 2026 - $DRTS